Not found VIEW CLINICAL PROFILE

Eric H. Bernicker, MD

Associate Professor of Clinical Medicine in Oncology, Institute for Academic Medicine
Associate Clinical Member, Research Institute
Houston Methodist
Weill Cornell Medical College


VIEW CLINICAL PROFILE
Biography

Dr. Bernicker earned his medical degree from Baylor College of Medicine in Houston, TX in 1990. Subsequently, he completed his residency at Baylor Affiliated Hospitals and was chief medical resident at Ben Taub General Hospital from 1993–1994. Dr. Bernicker held a faculty appointment at Baylor College of Medicine as a clinical assistant professor from 1996–2012 before joining the Houston Methodist Cancer Center in January 2013, where he serves as director of Medical Thoracic Oncology. As a physician-scientist, Dr. Bernicker oversees the expansion of clinical trials at The Methodist Hospital relating to Thoracic Oncology with all stages of disease, a combination of SWOG trials, and industry trials of novel targeted agents. 

Description of Research

Dr. Bernicker’s research focuses on looking at different therapeutic approaches, such as targeted therapies and immunotherapies, in the treatment of lung cancer. By understanding how to identify patients at risk for relapse after surgery or those who can be spared the toxicities of chemotherapy, the immune system can be stimulated to preferentially destroy tumor cells, spare normal tissues, and improve patient survival along with the development of less toxic therapeutics. Eventually, the goal is to be able to offer new therapies and clinical trials to patients at Methodist with any stage of non-small cell lung cancer or small cell lung cancer.

Areas Of Expertise

Lung cancer Cancer research Targeted therapeutics
Education & Training

MD, Baylor College of Medicine
Residency, Baylor College of Medicine
Clinical Fellowship, Baylor College of Medicine
Internship, Dallas County Hospital -Parkland Memorial Hospital
Active Clinical Trials

A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Subjects With Extensive Stage Small Cell Lung Cancer (MERU)

NCT03033511


Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-small Cell Lung Cancers

NCT02595944


ENSIGN: Phase II Window of Opportunity Trial of Stereotactic Body Radiation Therapy and In Situ Gene Therapy Followed by Nivolumab in Metastatic Squamous or Non-Squamous Non-Small Cell Lung Carcinoma

NCT02831933


A Phase III, Open-Label, Randomized Study to Investigate the Efficacy and Safety of Atezolizumab (Anti-PD-L1 Antibody) Compared With Best Supportive Care Following Adjuvant Cisplatin-Based Chemotherapy in Patients With Completely Resected Stage IB-IIIA

NCT02486718


A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Placebo for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein

NCT02201992


View All
Publications

Relationship between clinical features, GEP class, and PRAME expression in uveal melanoma
Schefler, AC, Koca, E, Bernicker, EH & Correa, ZM 2019, Graefes Archive for Clinical and Experimental Ophthalmology. https://doi.org/10.1007/s00417-019-04335-w

Update on emerging biomarkers in lung cancer
Bernicker, EH, Allen, TC & Cagle, PT 2019, Journal of Thoracic Disease, vol. 11, pp. S81-S88. https://doi.org/10.21037/jtd.2019.01.46

Combined blockade of activating ERBB2 mutations and ER results in synthetic lethality of ERþ/HER2 mutant breast cancer
Croessmann, S, Formisano, L, Kinch, LN, Gonzalez-Ericsson, PI, Sudhan, DR, Nagy, RJ, Mathew, A, Bernicker, EH, Cristofanilli, M, He, J, Cutler, RE, Lalani, AS, Miller, VA, Lanman, RB, Grishin, NV & Arteaga, CL 2019, Clinical Cancer Research, vol. 25, no. 1, pp. 277-289. https://doi.org/10.1158/1078-0432.CCR-18-1544

Disparities in the Treatment and Outcome of Stage I Non–Small-Cell Lung Cancer in the 21st Century
Dalwadi, SM, Lewis, GD, Bernicker, EH, Butler, EB, Teh, BS & Farach, AM 2019, Clinical Lung Cancer. https://doi.org/10.1016/j.cllc.2018.11.004

Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors guideline from the college of American pathologists, the international association for the study of lung cancer, and the association for molecular pathology
Lindeman, NI, Cagle, PT, Aisner, DL, Arcila, ME, Beasley, MB, Bernicker, EH, Colasacco, C, Dacic, S, Hirsch, FR, Kerr, K, Kwiatkowski, DJ, Ladanyi, M, Nowak, JA, Sholl, L, Temple-Smolkin, R, Solomon, B, Souter, LH, Thunnissen, E, Tsao, MS, Ventura, CB, Wynes, MW & Yatabe, Y 2018, Archives of Pathology and Laboratory Medicine, vol. 142, no. 3, pp. 321-346. https://doi.org/10.5858/arpa.2017-0388-CP

Correlation between programmed death receptor-1 expression in tumor-infiltrating lymphocytes and programmed death ligand-1 expression in non-small cell lung carcinoma
Monroig-Bosque, PDC, Driver, B, Morales-Rosado, JA, Deavers, M, Tacha, D, Bernicker, E, Cagle, PT & Miller, RA 2018, Archives of Pathology and Laboratory Medicine, vol. 142, no. 11, pp. 1388-1393. https://doi.org/10.5858/arpa.2017-0516-OA

Evaluation of the prescribing patterns, adverse effects, and drug interactions of oral chemotherapy agents in an outpatient cancer center
Solomon, JM, Ajewole, VB, Schneider, AM, Sharma, M & Bernicker, EH 2018, Journal of Oncology Pharmacy Practice. https://doi.org/10.1177/1078155218798150

Hybrid Capture–Based Genomic Profiling of Circulating Tumor DNA from Patients with Advanced Non–Small Cell Lung Cancer
Schrock, AB, Welsh, A, Chung, JH, Pavlick, D, Bernicker, EH, Creelan, BC, Forcier, B, Ross, JS, Stephens, PJ, Ali, SM, Dagogo-Jack, I, Shaw, AT, Li, T, Ou, SHI & Miller, VA 2018, Journal of Thoracic Oncology. https://doi.org/10.1016/j.jtho.2018.10.008

Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors. Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology
Lindeman, NI, Cagle, PT, Aisner, DL, Arcila, ME, Beasley, MB, Bernicker, E, Colasacco, C, Dacic, S, Hirsch, FR, Kerr, K, Kwiatkowski, DJ, Ladanyi, M, Nowak, JA, Sholl, L, Temple-Smolkin, R, Solomon, B, Souter, LH, Thunnissen, E, Tsao, MS, Ventura, CB, Wynes, MW & Yatabe, Y 2018, Journal of Thoracic Oncology. https://doi.org/10.1016/j.jtho.2017.12.001

Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors. Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology
Lindeman, NI, Cagle, PT, Aisner, DL, Arcila, ME, Beasley, MB, Bernicker, E, Colasacco, C, Dacic, S, Hirsch, FR, Kerr, K, Kwiatkowski, DJ, Ladanyi, M, Nowak, JA, Sholl, L, Temple-Smolkin, R, Solomon, B, Souter, LH, Thunnissen, E, Tsao, MS, Ventura, CB, Wynes, MW & Yatabe, Y 2018, Journal of Molecular Diagnostics. https://doi.org/10.1016/j.jmoldx.2017.11.004

Management of pathologic node-positive disease following initial surgery for clinical T1-2 N0 esophageal cancer: patterns of care and outcomes from the national cancer data base
Haque, WM, Verma, V, Bernicker, EH, Butler, EB & Teh, BS 2017, Acta Oncologica, pp. 1-8. https://doi.org/10.1080/0284186X.2017.1409435

Programmed death ligand-1 (pd-l1) expression in either tumor cells or tumor-infiltrating immune cells correlates with solid and high-grade lung adenocarcinomas
Driver, BR, Miller, RA, Miller, T, Deavers, M, Gorman, B, Mody, D, Ge, Y, Barrios, R, Bernicker, E, Kim, M & Cagle, PT 2017, Archives of Pathology and Laboratory Medicine, vol. 141, no. 11, pp. 1529-1532. https://doi.org/10.5858/arpa.2017-0028-OA

Biomarkers for selection of therapy for adenocarcinoma of the lung
Bernicker, EH, Miller, RA & Cagle, PT 2017, Journal of Oncology Practice, vol. 13, no. 4, pp. 221-227. https://doi.org/10.1200/JOP.2016.019182

Practice Patterns and Outcomes in Elderly Stage I Non-Small-cell Lung Cancer: A 2004 to 2012 SEER Analysis
Dalwadi, SM, Szeja, SS, Bernicker, EH, Butler, EB, Teh, BS & Farach, AM 2017, Clinical Lung Cancer. https://doi.org/10.1016/j.cllc.2017.11.004

First-line immune therapy - Implications for pathologists
Miller, RA, Cagle, PT & Bernicker, EH 2016, Archives of Pathology and Laboratory Medicine, vol. 140, no. 8, pp. 739-740. https://doi.org/10.5858/arpa.2016-0904-ED

Chemotherapy in non-small cell lung cancer: opportunities for advancement
Akhtari, M, Bernicker, EH & Teh, BS 2016, Chinese Journal of Lung Cancer, vol. 35, no. 1, pp. 56. https://doi.org/10.1186/s40880-016-0119-x

Impact of recent developments in lung cancer on the practice of pathology
Cagle, PT, Allen, TC, Bernicker, EH, Ge, Y, Haque, A & Barrios, R 2016, Archives of Pathology and Laboratory Medicine, vol. 140, no. 4, pp. 322-325. https://doi.org/10.5858/arpa.2015-0535-SA

Next-generation sequencing of a cohort of pulmonary large cell carcinomas reclassified by world health organization 2015 criteria
Driver, BR, Portier, BP, Mody, DR, Deavers, M, Bernicker, EH, Kim, MP, Teh, BS, Santacruz, JF, Kopas, L, Munden, RF & Cagle, PT 2016, Archives of Pathology and Laboratory Medicine, vol. 140, no. 4, pp. 312-317. https://doi.org/10.5858/arpa.2015-0361-OA

Next-generation sequencing and immunotherapy biomarkers: A medical oncology perspective
Bernicker, E 2016, Archives of Pathology and Laboratory Medicine, vol. 140, no. 3, pp. 245-248. https://doi.org/10.5858/arpa.2015-0287-SA

Challenges to biomarker testing for PD-1/PD-L1 checkpoint inhibitors for lung cancer
Cagle, PT & Bernicker, EH 2015, Archives of Pathology and Laboratory Medicine, vol. 139, no. 12, pp. 1477-1478. https://doi.org/10.5858/arpa.2015-0902-ED

VIEW FULL PUBLICATIONS
Live Chat Available